Alpha 2.0
Login Register
» Authors » Aaron H Burstein

Aaron H Burstein

Explore the profile of Aaron H Burstein including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 558
Followers 0
Related Specialties
Pharmacology
Neurology
Physiology
Top 10 Co-Authors
Helene M Faessel
Stephen C Piscitelli
David J Clark
Megan A Gibbs
Qinying Zhao
Melissa OGorman
Jaren W Landen
Terence Fullerton
Judith Falloon
Scot Styren
Published In
J Clin Pharmacol
Pharmacotherapy
Clin Infect Dis
Crit Care Med
Ann Pharmacother
Affiliations
Soon will be listed here.
Recent Articles
1.
Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis
Burstein A, Brantley S, Dunn I, Altstiel L, Schmith V
Clin Pharmacol Drug Dev . 2019 Apr; 8(4):426-435. PMID: 30934161
Azeliragon is an inhibitor of the receptor for advanced glycation end products being developed for the treatment of Alzheimer's disease. The objective of the current analysis was to evaluate the...
2.
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
Landen J, Cohen S, Billing Jr C, Cronenberger C, Styren S, Burstein A, et al.
Alzheimers Dement (N Y) . 2017 Oct; 3(3):339-347. PMID: 29067341
Introduction: Multiple intravenous doses of ponezumab, an anti-amyloid antibody, were evaluated in subjects with mild-to-moderate Alzheimer's disease (AD). Methods: In part A, 77 subjects were randomized to ponezumab 0.1, 0.5,...
3.
Effect of TTP488 in patients with mild to moderate Alzheimer's disease
Burstein A, Grimes I, Galasko D, Aisen P, Sabbagh M, Mjalli A
BMC Neurol . 2014 Jan; 14:12. PMID: 24423155
Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). A previous report describes decreased...
4.
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease
Burstein A, Zhao Q, Ross J, Styren S, Landen J, Ma W, et al.
Clin Neuropharmacol . 2013 Jan; 36(1):8-13. PMID: 23334069
Objective: Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously...
5.
A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation
Faessel H, Obach R, Rollema H, Ravva P, Williams K, Burstein A
Clin Pharmacokinet . 2010 Nov; 49(12):799-816. PMID: 21053991
Varenicline tartrate (Chantix®/Champix®) is a selective partial agonist of the α(4)β(2) nicotinic acetylcholine receptor and is approved as an aid to smoking cessation. The usual oral dosage in adults is...
6.
Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers
Zhao Q, Schwam E, Fullerton T, OGorman M, Burstein A
J Clin Pharmacol . 2010 May; 51(4):492-501. PMID: 20466870
This study was designed to investigate the multiple-dose pharmacokinetics, safety, and tolerability of the selective α4β2 nicotinic acetylcholine partial agonist, varenicline, in elderly (65-85 years old) nonsmokers. Fifty male and...
7.
Increase in tiagabine serum concentration with coadministration of gemfibrozil
Burstein A, Boudreau E, Theodore W
Ann Pharmacother . 2009 Feb; 43(2):379-82. PMID: 19193595
Objective: To report a case of possible acute tiagabine toxicity secondary to administration of gemfibrozil. Case Summary: A 39-year-old male was taking tiagabine 16 mg orally 3 times per day...
8.
Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humans
Shaffer C, Gunduz M, Vaz A, Venkatakrishnan K, Burstein A
Drug Metab Dispos . 2008 Jan; 36(4):655-62. PMID: 18180269
The metabolism and disposition of N-[3-fluoro-4-[2-(propylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo-1H-indole-3-carboxamide (1), a potent subtype-selective partial agonist at the gamma-aminobutyric acid type A receptor complex, were elucidated in humans following a p.o. dose of N-[3-fluoro-4-[2-(propylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo-1H-[3-(14)C]indole-3-carboxamide...
9.
Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study
Burstein A, Clark D, OGorman M, Willavize S, Brayman T, Grover G, et al.
J Clin Pharmacol . 2007 Oct; 47(11):1421-9. PMID: 17962429
This study investigated the effect of varenicline on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in 24 adult smokers and compared these findings with data generated using...
10.
Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study
Shang Y, Gibbs M, Marek G, Stiger T, Burstein A, Marek K, et al.
J Clin Psychopharmacol . 2007 Jan; 27(1):71-5. PMID: 17224717
Both positron emission tomography and single photon emission computed tomography (SPECT) studies suggest that saturation of serotonin transporters (SERT) is present during treatment with therapeutic doses of selective serotonin reuptake...